Richard Rawson, Ph.D.
UCLA Integrated Substance Abuse Programs
Professor and Associate Director
Amphetamine-type stimulants (ATS) constitute the 2nd most widely used illicit drug category in the world, following cannabis. Globally, the biggest impact from ATS use (amphetamine, methamphetamine, and captagon) has been identified in the Middle East, Southeast Asia, and North America. ATS affects the mesolimbic reward system in the brain causing increased levels of dopamine. Although initial use results in positive physical and psychological reactions (increased confidence, alertness and energy, enhanced mood and sex drive), a variety of negative and damaging consequences occur after prolonged use (cardiovascular disease, pulmonary and neurologic problems, skin infections and dental decay). In addition, other chronic diseases highly associated with ATS use include hepatitis C and HIV. Specific clinical challenges and special populations are reviewed when treating ATS users. Psychological and behavioral treatments currently have best evidence of efficacy, but ongoing research is being done to identify effective pharmacological treatment strategies.
Learning Objectives:
1. Increase knowledge of amphetamine-type stimulants, the medical consequences, and how it effects the brain
2. Review evidence-based treatment models for ATS including behavioral and pharmacological strategies that are currently under study
UCLA ISAP Website: http://www.uclaisap.org/video/Research-Training-Series/